by Jordana Choucair | Mar 14, 2022 | Opioid/Substance Use Disorders
Black Americans fatally overdosed in 2020 at a higher rate than white Americans for the first time since 1999. The rise of fentanyl, which is more deadly than heroin or prescription opioids, is driving the overdose rate higher and changing its demographics. The...
by Jordana Choucair | Mar 11, 2022 | Opioid/Substance Use Disorders
The HHS Office of the Inspector General (OIG) authored a new advisory legal opinion that clears the way for Boston-based DynamiCare Health to use of contingency management – a harm reduction technique that pays people addicted to drugs to remain clean. Under the...
by Jordana Choucair | Mar 10, 2022 | Opioid/Substance Use Disorders
A judge approved a new $6 billion settlement between the Sackler family and dozens of local governments that accused Purdue Pharma of fueling the opioid crisis, overruling objections from the Department of Justice and 20 states. The deal, which replaces an earlier...
by Jordana Choucair | Mar 9, 2022 | Opioid/Substance Use Disorders
Insurers for some of the largest drug makers, distributors, and pharmacies are refusing to pay a $32 billion bill to help cover costs related to opioid addiction. A Delaware Supreme Court ruled in January that Chubb Ltd. didn’t have to pay to defend Rite Aid Corp....
by Jordana Choucair | Mar 8, 2022 | Opioid/Substance Use Disorders
Three congressmen unveiled new bipartisan legislation that would permanently ban illicit versions of fentanyl. Thus far, Congress has not acted on a long-term solution over concerns that a permanent ban could stifle scientific research into fentanyl analogues and the...
by Jordana Choucair | Mar 4, 2022 | Opioid/Substance Use Disorders
OxyContin maker Purdue Pharma and the Sackler family have struck an agreement to pay up to $6 billion to settle lawsuits over the company’s role in fueling the opioid crisis. The new settlement is up from the $4.55 deal reached last year and is contingent upon...
Recent Comments